These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 34586889

  • 1. Evaluation of MicroScan WalkAway for Determination of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Susceptibility in Carbapenem-Resistant Gram-Negative Bacilli.
    Ito CAS, Bail L, Arend LNVS, Silva KO, Michelotto SS, Nogueira KDS, Tuon FF.
    J Clin Microbiol; 2021 Nov 18; 59(12):e0153621. PubMed ID: 34586889
    [Abstract] [Full Text] [Related]

  • 2. The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosa.
    Gill CM, Aktaþ E, Alfouzan W, Bourassa L, Brink A, Burnham CD, Canton R, Carmeli Y, Falcone M, Kiffer C, Marchese A, Martinez O, Pournaras S, Satlin M, Seifert H, Thabit AK, Thomson KS, Villegas MV, Nicolau DP, ERACE-PA Global Study Group.
    Eur J Clin Microbiol Infect Dis; 2021 Dec 18; 40(12):2533-2541. PubMed ID: 34291323
    [Abstract] [Full Text] [Related]

  • 3. Verification of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Susceptibility Testing Methods against Carbapenem-Resistant Enterobacteriaceae and Pseudomonas aeruginosa.
    Shields RK, Clancy CJ, Pasculle AW, Press EG, Haidar G, Hao B, Chen L, Kreiswirth BN, Nguyen MH.
    J Clin Microbiol; 2018 Feb 18; 56(2):. PubMed ID: 29167294
    [Abstract] [Full Text] [Related]

  • 4. Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the In Vitro Activities of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa.
    Yin D, Wu S, Yang Y, Shi Q, Dong D, Zhu D, Hu F, China Antimicrobial Surveillance Network (CHINET) Study Group.
    Antimicrob Agents Chemother; 2019 Apr 18; 63(4):. PubMed ID: 30617091
    [Abstract] [Full Text] [Related]

  • 5. Phenotypic and genotypic profile of ceftolozane/tazobactam-non-susceptible, carbapenem-resistant Pseudomonas aeruginosa.
    Gill CM, Nicolau DP, ERACE-PA Global Study Group.
    J Antimicrob Chemother; 2022 Dec 23; 78(1):252-256. PubMed ID: 36411249
    [Abstract] [Full Text] [Related]

  • 6. Comparison of ceftazidime-avibactam and ceftolozane-tazobactam in vitro activities when tested against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017-2018).
    Sader HS, Flamm RK, Carvalhaes CG, Castanheira M.
    Diagn Microbiol Infect Dis; 2020 Mar 23; 96(3):114833. PubMed ID: 31924426
    [Abstract] [Full Text] [Related]

  • 7. Assessment of Ceftazidime-Avibactam 30/20-μg Disk, Etest versus Broth Microdilution Results When Tested against Enterobacterales Clinical Isolates.
    Han R, Yang X, Yang Y, Guo Y, Yin D, Ding L, Wu S, Zhu D, Hu F.
    Microbiol Spectr; 2022 Feb 23; 10(1):e0109221. PubMed ID: 35019685
    [Abstract] [Full Text] [Related]

  • 8. Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections.
    Sader HS, Castanheira M, Duncan LR, Mendes RE.
    Int J Infect Dis; 2021 Dec 23; 113():279-281. PubMed ID: 34670144
    [Abstract] [Full Text] [Related]

  • 9. Antimicrobial susceptibility profile of ceftolozane/tazobactam, ceftazidime/avibactam and cefiderocol against carbapenem-resistant Pseudomonas aeruginosa clinical isolates from Türkiye.
    Buyukyanbolu E, Genc L, Cyr EA, Karakus M, Comert F, Otlu B, Aktas E, Nicolau DP.
    Eur J Clin Microbiol Infect Dis; 2024 Sep 23; 43(9):1787-1794. PubMed ID: 38995343
    [Abstract] [Full Text] [Related]

  • 10. Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
    Alatoom A, Elsayed H, Lawlor K, AbdelWareth L, El-Lababidi R, Cardona L, Mooty M, Bonilla MF, Nusair A, Mirza I.
    Int J Infect Dis; 2017 Sep 23; 62():39-43. PubMed ID: 28610832
    [Abstract] [Full Text] [Related]

  • 11. In Vitro Activity of New β-Lactam-β-Lactamase Inhibitor Combinations and Comparators against Clinical Isolates of Gram-Negative Bacilli: Results from the China Antimicrobial Surveillance Network (CHINET) in 2019.
    Guo Y, Han R, Jiang B, Ding L, Yang F, Zheng B, Yang Y, Wu S, Yin D, Zhu D, Hu F, China Antimicrobial Surveillance Network (CHINET) Study Group.
    Microbiol Spectr; 2022 Aug 31; 10(4):e0185422. PubMed ID: 35862963
    [Abstract] [Full Text] [Related]

  • 12. Ceftazidime-avibactam and ceftolozane-tazobactam susceptibility of multidrug resistant Pseudomonas aeruginosa strains in Hungary.
    O'Neall D, Juhász E, Tóth Á, Urbán E, Szabó J, Melegh S, Katona K, Kristóf K.
    Acta Microbiol Immunol Hung; 2020 Mar 26; 67(1):61-65. PubMed ID: 32208923
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of in vitro activity of ceftazidime/avibactam and ceftolozane/tazobactam against MDR Pseudomonas aeruginosa isolates from Qatar.
    Sid Ahmed MA, Abdel Hadi H, Hassan AAI, Abu Jarir S, Al-Maslamani MA, Eltai NO, Dousa KM, Hujer AM, Sultan AA, Soderquist B, Bonomo RA, Ibrahim EB, Jass J, Omrani AS.
    J Antimicrob Chemother; 2019 Dec 01; 74(12):3497-3504. PubMed ID: 31504587
    [Abstract] [Full Text] [Related]

  • 14. Antimicrobial Activity of Ceftolozane-Tazobactam, Ceftazidime-Avibactam, and Cefiderocol against Multidrug-Resistant Pseudomonas aeruginosa Recovered at a German University Hospital.
    Weber C, Schultze T, Göttig S, Kessel J, Schröder A, Tietgen M, Besier S, Burbach T, Häussler S, Wichelhaus TA, Hack D, Kempf VAJ, Hogardt M.
    Microbiol Spectr; 2022 Oct 26; 10(5):e0169722. PubMed ID: 36190424
    [Abstract] [Full Text] [Related]

  • 15. Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds.
    Grupper M, Sutherland C, Nicolau DP.
    Antimicrob Agents Chemother; 2017 Oct 26; 61(10):. PubMed ID: 28739780
    [Abstract] [Full Text] [Related]

  • 16. In Vitro Activity of Ceftolozane-Tazobactam, Imipenem-Relebactam, Ceftazidime-Avibactam, and Comparators against Pseudomonas aeruginosa Isolates Collected in United States Hospitals According to Results from the SMART Surveillance Program, 2018 to 2020.
    Karlowsky JA, Lob SH, DeRyke CA, Hilbert DW, Wong MT, Young K, Siddiqui F, Motyl MR, Sahm DF.
    Antimicrob Agents Chemother; 2022 May 17; 66(5):e0018922. PubMed ID: 35491836
    [Abstract] [Full Text] [Related]

  • 17. Activity of Ceftolozane-Tazobactam against Carbapenem-Resistant, Non-Carbapenemase-Producing Pseudomonas aeruginosa and Associated Resistance Mechanisms.
    Wi YM, Greenwood-Quaintance KE, Schuetz AN, Ko KS, Peck KR, Song JH, Patel R.
    Antimicrob Agents Chemother; 2018 Jan 17; 62(1):. PubMed ID: 29133568
    [Abstract] [Full Text] [Related]

  • 18. Phylogenetic analysis of resistance to ceftazidime/avibactam, ceftolozane/tazobactam and carbapenems in piperacillin/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patients.
    Zamudio R, Hijazi K, Joshi C, Aitken E, Oggioni MR, Gould IM.
    Int J Antimicrob Agents; 2019 Jun 17; 53(6):774-780. PubMed ID: 30831233
    [Abstract] [Full Text] [Related]

  • 19. Activity of ceftolozane/tazobactam against Gram-negative isolates among different infections in Hong Kong: SMART 2017-2019.
    Karlowsky JA, Lob SH, Khan A, Chen WT, Woo PCY, Seto WH, Ip M, Leung S, Wong QW, Chau RWY, DeRyke CA, Young K, Motyl MR, Sahm DF.
    J Med Microbiol; 2022 Apr 17; 71(4):. PubMed ID: 35451945
    [Abstract] [Full Text] [Related]

  • 20. Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam and Comparators Tested Against Pseudomonas aeruginosa and Klebsiella pneumoniae Isolates from United States Medical Centers in 2016-2018.
    Sader HS, Carvalhaes CG, Streit JM, Doyle TB, Castanheira M.
    Microb Drug Resist; 2021 Mar 17; 27(3):342-349. PubMed ID: 32762605
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.